Granted Patent
B2
US 12,417,533 · App. 18/398,846 · Granted Sep 16, 2025
Systems and methods for artificial intelligence-based image analysis for cancer assessment
Inventors:
Aseem Undvall Anand (Queens, NY); Karl Vilhelm Sjöstrand (Atlantic Highlands, NJ); Jens Filip Andreas Richter (Staffanstorp, SE)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Presented herein are systems and methods that provide for automated analysis of medical images to determine a predicted disease status (e.g., prostate cancer status) and/or a value corresponding to predicted risk of the disease status for a subject. The approaches described herein leverage artificial intelligence (AI) to analyze intensities of voxels in a functional image, such as a PET image, and determine a risk and/or likelihood that a subject's disease, e.g., cancer, is aggressive. The approaches described herein can provide predictions of whether a subject that presents a localized disease has and/or will develop aggressive disease, such as metastatic cancer. These predictions are generated in a fully automated fashion and can be used alone, or in combination with other cancer diagnostic metrics (e.g., to corroborate predictions and assessments or highlight potential errors). As such, they represent a valuable tool in support of improved cancer diagnosis and treatment.
Claims (42)
1. A method for determining a predicted disease status and/or a value corresponding to predicted risk of the disease status based on automated analysis of intensities of a three-dimensional (3D) functional image, the method comprising:
(a) receiving, by a processor of a computing device, a 3D anatomical image of a subject obtained using an anatomical imaging modality, wherein the 3D anatomical image comprises a graphical representation of tissue within the subject;
(b) identifying, by the processor, within the 3D anatomical image, a target volume of interest (VOI) corresponding to a prostate region of the subject;
(c) receiving, by the processor, a 3D functional image of the subject obtained using a functional imaging modality; and
(d) determining, by the processor, a predicted disease status of the subject and/or a value corresponding to predicted risk of the disease status of the subject using a machine learning module that (i) receives, as input, intensities of only those voxels of the 3D functional image identified as corresponding to the target VOI of the anatomical image and (ii) does not receive, as input, intensities of other voxels of the 3D functional image.
2. The method of claim 1 , wherein the method comprises identifying the voxels of the 3D functional image corresponding to the target VOI of the anatomical image by:
identifying, by the processor, within the 3D functional image, a 3D prostate volume corresponding to the target VOI identified within the 3D anatomical image and identifying voxels of the 3D functional image lying within the 3D prostate volume as corresponding to the target VOI of the anatomical image.
3. The method of claim 1 , wherein the machine learning module receives, as input, only intensities of the voxels of the 3D functional image identified as corresponding to the target VOI of the anatomical image.
4. The method of claim 1 , wherein the machine learning module further receives, as input, one or more clinical variables.
5. The method of claim 4 , wherein the one or more clinical variables comprise one or more members selected from the group consisting of:
a race/ethnicity;
a prostate specific antigen (PSA) level and/or velocity;
a hemoglobin level;
a lactate dehydrogenase level;
an albumin level;
a clinical T stage;
a biopsy Gleason score; and
a percentage positive core score.
6. The method of claim 1 , comprising determining the predicted disease status, wherein the predicted disease status is a classification corresponding to a prediction of aggressive disease status.
7. The method of claim 6 , wherein the classification comprises one or more of the following classes corresponding to predictions of whether the subject has and/or likely will develop one or more metastases:
an overall metastases class, wherein assignment to the overall metastases class corresponds to a prediction that the subject has and/or will likely develop one or more metastases;
one or more particular metastases class, each corresponding to a particular type of metastases wherein assignment to the particular metastases class corresponds to a prediction that the subject has and/or will likely develop the particular type of metastases; and
a no metastases class, wherein assignment to the no metastases class corresponds to a prediction that the subject had not and/or is not likely to develop one or more metastases.
8. The method of claim 6 , wherein the machine learning module generates, as output, one or more likelihood values representing likelihood(s) of overall metastases and/or one or more particular types of metastases, and wherein determining the classification comprises comparing the one or more likelihood values with one or more thresholds.
9. The method of claim 1 , wherein the method comprises determining the value corresponding to predicted risk of the disease status of the subject, and wherein the disease status is an aggressive disease status.
10. The method of claim 9 , wherein the value represents a likelihood that the subject has and/or will develop one or more metastases.
11. The method of claim 10 , wherein the value represents a likelihood that the subject has and/or will develop one or more of a particular type of metastases.
12. The method of claim 9 , comprising determining a plurality of values, each corresponding to a particular type of metastases and representing a likelihood that the subject has and/or will develop one or more of the particular type of metastases.
13. The method of claim 1 , wherein the disease is prostate cancer.
14. The method of claim 1 , wherein the machine learning module comprises a convolutional neural network (CNN).
15. The method of claim 1 , wherein the anatomical image is a CT scan.
16. The method of claim 1 , wherein the functional image is a PET image obtained following administration of a radiopharmaceutical to the subject.
17. The method of claim 16 , wherein the radiopharmaceutical comprises a prostate specific membrane antigen (PSMA) binding agent.
18. The method of claim 17 , wherein the PSMA binding agent is [18F]DCFPyL.
19. The method of claim 1 , wherein the functional image is a SPECT image.
20. A system for determining a predicted disease status and/or a value corresponding to predicted risk of the disease status based on automated analysis of intensities of a three-dimensional (3D) functional image, the system comprising:
a processor of a computing device; and
a memory having instructions stored thereon, wherein the instructions, when executed by the processor, cause the processor to:
(a) receive a 3D anatomical image of a subject obtained using an anatomical imaging modality, wherein the 3D anatomical image comprises a graphical representation of tissue within the subject;
(b) identify, within the 3D anatomical image, a target volume of interest (VOI) corresponding to a prostate region of the subject;
(c) receive a 3D functional image of the subject obtained using a functional imaging modality; and
(d) determine a predicted disease status of the subject and/or a value corresponding to predicted risk of the disease status of the subject using a machine learning module that (i) receives, as input, intensities of only those voxels of the 3D functional identified as corresponding to the target VOI of the anatomical image and (ii) does not receive, as input, intensities of other voxels of the 3D functional image.
Assignments (3)
SECURITY INTEREST
Recorded Dec 17, 2025
From: LANTHEUS MEDICAL IMAGING, INC.; PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A., AS COLLATERAL AGENT, NATIONAL BANKING ASSOCIATION
Reel/Frame 073250/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 8, 2024
From: ANAND, ASEEM UNDVALL; RICHTER, JENS FILIP ANDREAS
To: EXINI DIAGNOSTICS AB
Reel/Frame 068227/0428 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 8, 2024
From: SJÖSTRAND, KARL VILHELM
To: PROGENICS PHARMACEUTICALS, INC.
Reel/Frame 068227/0440 →
Continuity (4)
Continuation
17762796
Provisional Application
62907180
· Sep 27, 2019
References Cited (373)
US 5762608A
· Warne et al.
· 1998
[cited by applicant]
US 6944330B2
· Novak et al.
· 2005
[cited by applicant]
US 7450747B2
· Jabri et al.
· 2008
[cited by applicant]
US 7751605B2
· Gündel et al.
· 2010
[cited by applicant]
US 7876938B2
· Huang et al.
· 2011
[cited by applicant]
US 7935055B2
· Burckhardt
· 2011
[cited by applicant]
US 7970194B2
· Kimura
· 2011
[cited by applicant]
US 8199985B2
· Jakobsson et al.
· 2012
[cited by applicant]
US 8211401B2
· Babich et al.
· 2012
[cited by applicant]
US 8467856B2
· Renisch et al.
· 2013
[cited by applicant]
US 8538166B2
· Gordon et al.
· 2013
[cited by applicant]
US 8606349B2
· Rousso et al.
· 2013
[cited by applicant]
US 8705887B2
· Ma et al.
· 2014
[cited by applicant]
US 8778305B2
· Pomper et al.
· 2014
[cited by applicant]
US 8855387B2
· Hamadeh et al.
· 2014
[cited by applicant]
US 8962799B2
· Babich et al.
· 2015
[cited by applicant]
US 8995736B2
· Kaufman et al.
· 2015
[cited by applicant]
US 9002081B2
· Brown
· 2015
[cited by applicant]
US 9028800B2
· D'Souza et al.
· 2015
[cited by applicant]
US 9466133B2
· Sowards-Emmerd et al.
· 2016
[cited by applicant]
US 9710915B2
· Firouzian et al.
· 2017
[cited by applicant]
US 9721340B2
· Gillies et al.
· 2017
[cited by applicant]
US RE47609E
· Hamadeh et al.
· 2019
[cited by applicant]
US 20030215120A1
· Uppaluri et al.
· 2003
[cited by applicant]
US 20050065421A1
· Burckhardt
· 2005
[cited by applicant]
US 20050281381A1
· Guendel
· 2005
[cited by applicant]
US 20060062425A1
· Shen et al.
· 2006
[cited by applicant]
US 20060064396A1
· Wei et al.
· 2006
[cited by applicant]
US 20060078183A1
· deCharms
· 2006
[cited by applicant]
US 20070081712A1
· Huang et al.
· 2007
[cited by applicant]
US 20070081713A1
· Jerebko
· 2007
[cited by applicant]
US 20070100225A1
· Maschke
· 2007
[cited by applicant]
US 20070115204A1
· Budz et al.
· 2007
[cited by applicant]
US 20080027315A1
· McGinnis
· 2008
[cited by applicant]
US 20090309874A1
· Salganicoff et al.
· 2009
[cited by applicant]
US 20090311182A1
· Wang et al.
· 2009
[cited by applicant]
US 20100032575A1
· Lagaru et al.
· 2010
[cited by applicant]
US 20100080434A1
· Seifert et al.
· 2010
[cited by applicant]
US 20100215581A1
· Hoffmann
· 2010
[cited by applicant]
US 20100266170A1
· Khamene et al.
· 2010
[cited by applicant]
US 20100322488A1
· Virtue et al.
· 2010
[cited by applicant]
US 20110007954A1
· Suehling et al.
· 2011
[cited by applicant]
US 20110063288A1
· Valadez
· 2011
[cited by applicant]
US 20110255763A1
· Bogoni et al.
· 2011
[cited by applicant]
US 20120123253A1
· Renisch et al.
· 2012
[cited by applicant]
US 20130038707A1
· Cunningham et al.
· 2013
[cited by applicant]
US 20130094704A1
· Hamadeh et al.
· 2013
[cited by applicant]
US 20130129168A1
· Ross
· 2013
[cited by applicant]
US 20130211231A1
· Sundarapandian et al.
· 2013
[cited by applicant]
US 20130281841A1
· Everett et al.
· 2013
[cited by applicant]
US 20140105471A1
· Brown
· 2014
[cited by applicant]
US 20140193336A1
· Rousso et al.
· 2014
[cited by applicant]
US 20150003703A1
· Franz et al.
· 2015
[cited by applicant]
US 20150063667A1
· Sprencz et al.
· 2015
[cited by applicant]
US 20150110716A1
· Armor
· 2015
[cited by applicant]
US 20150119704A1
· Roth et al.
· 2015
[cited by applicant]
US 20150287188A1
· Gazit et al.
· 2015
[cited by applicant]
US 20150331995A1
· Zhao et al.
· 2015
[cited by applicant]
US 20150356730A1
· Grove et al.
· 2015
[cited by applicant]
US 20160180042A1
· Menon et al.
· 2016
[cited by applicant]
US 20160203263A1
· Maier et al.
· 2016
[cited by applicant]
US 20160275674A1
· Rivet-Sabourin et al.
· 2016
[cited by applicant]
US 20160335395A1
· Wu et al.
· 2016
[cited by applicant]
US 20170083682A1
· McNutt et al.
· 2017
[cited by applicant]
US 20170112577A1
· Bonutti et al.
· 2017
[cited by applicant]
US 20180140260A1
· Taguchi et al.
· 2018
[cited by applicant]
US 20180144828A1
· Baker
· 2018
[cited by applicant]
US 20180259608A1
· Golden et al.
· 2018
[cited by applicant]
US 20180360402A1
· Carmi
· 2018
[cited by applicant]
US 20190038239A1
· Flohr et al.
· 2019
[cited by applicant]
US 20190105009A1
· Siemionow et al.
· 2019
[cited by applicant]
US 20190105200A1
· Hipsley
· 2019
[cited by applicant]
US 20190209116A1
· Sjostrand et al.
· 2019
[cited by applicant]
US 20190388049A1
· Gupta et al.
· 2019
[cited by applicant]
US 20200027559A1
· Baker
· 2020
[cited by applicant]
US 20200051238A1
· El Harouni et al.
· 2020
[cited by applicant]
US 20200074634A1
· Kecskemethy et al.
· 2020
[cited by applicant]
US 20200085382A1
· Taerum et al.
· 2020
[cited by applicant]
US 20200090328A1
· Takei et al.
· 2020
[cited by applicant]
US 20200097701A1
· Chukka et al.
· 2020
[cited by applicant]
US 20200126666A1
· Baker
· 2020
[cited by applicant]
US 20200170604A1
· Yildirim et al.
· 2020
[cited by applicant]
US 20200193594A1
· Georgescu et al.
· 2020
[cited by applicant]
US 20200193603A1
· Golden et al.
· 2020
[cited by applicant]
US 20200245960A1
· Richter et al.
· 2020
[cited by applicant]
US 20200311919A1
· Grimmer et al.
· 2020
[cited by applicant]
US 20200315455A1
· Lee et al.
· 2020
[cited by applicant]
US 20200337658A1
· Sjostrand et al.
· 2020
[cited by applicant]
US 20200352518A1
· Lyman et al.
· 2020
[cited by applicant]
US 20200357117A1
· Lyman et al.
· 2020
[cited by applicant]
US 20200357118A1
· Yao et al.
· 2020
[cited by applicant]
US 20200357521A1
· Baker
· 2020
[cited by applicant]
US 20200410672A1
· Katscher et al.
· 2020
[cited by applicant]
US 20210032206A1
· Neumaier et al.
· 2021
[cited by applicant]
US 20210082547A1
· Yao et al.
· 2021
[cited by applicant]
US 20210093249A1
· Anand et al.
· 2021
[cited by applicant]
US 20210183485A1
· Yao et al.
· 2021
[cited by applicant]
US 20210233633A1
· Lints et al.
· 2021
[cited by applicant]
US 20210334974A1
· Johnsson et al.
· 2021
[cited by applicant]
US 20210335480A1
· Johnsson et al.
· 2021
[cited by applicant]
US 20220005586A1
· Brynolfsson et al.
· 2022
[cited by applicant]
US 20220375612A1
· Baker
· 2022
[cited by applicant]
US 20220398724A1
· Anand et al.
· 2022
[cited by applicant]
US 20230148980A1
· Sjöstrand et al.
· 2023
[cited by applicant]
US 20230316530A1
· Richter et al.
· 2023
[cited by applicant]
US 20230351586A1
· Brynolfsson et al.
· 2023
[cited by applicant]
US 20230410985A1
· Brynolfsson et al.
· 2023
[cited by applicant]
US 20240029252A1
· Ichinose et al.
· 2024
[cited by applicant]
US 20240285248A1
· Sjöstrand et al.
· 2024
[cited by applicant]
US 20240354940A1
· Sjöstrand et al.
· 2024
[cited by applicant]
US 20250061580A1
· Richter et al.
· 2025
[cited by applicant]
US 20250062029A1
· Baker
· 2025
[cited by applicant]
US 20250104225A1
· Sjöstrand et al.
· 2025
[cited by applicant]
CN 1200520A
· 1998
[cited by applicant]
CN 1518719A
· 2004
[cited by applicant]
CN 101528267A
· 2009
[cited by applicant]
CN 101639937A
· 2010
[cited by applicant]
CN 102096804A
· 2011
[cited by applicant]
CN 102361594A
· 2012
[cited by applicant]
CN 102438529A
· 2012
[cited by applicant]
CN 102947840A
· 2013
[cited by applicant]
CN 103607954A
· 2014
[cited by applicant]
CN 103930030A
· 2014
[cited by applicant]
CN 104463840A
· 2015
[cited by applicant]
CN 106127819A
· 2016
[cited by applicant]
CN 106558045A
· 2017
[cited by applicant]
CN 107563378A
· 2018
[cited by applicant]
CN 107644421A
· 2018
[cited by applicant]
CN 114219787A
· 2022
[cited by applicant]
EP 1426903A2
· 2004
[cited by applicant]
EP 1508872A1
· 2005
[cited by applicant]
EP 2816525A1
· 2014
[cited by applicant]
EP 3043318A1
· 2016
[cited by applicant]
EP 3811845A1
· 2021
[cited by applicant]
GB 2457577A
· 2009
[cited by applicant]
JP 2010029481A
· 2010
[cited by applicant]
JP 2011067594A
· 2011
[cited by applicant]
JP 2012533384A
· 2012
[cited by applicant]
JP 2014006130A
· 2014
[cited by applicant]
JP 2015513083A
· 2015
[cited by applicant]
JP 6013042B2
· 2016
[cited by applicant]
JP 2017500537A
· 2017
[cited by applicant]
JP 2017067489A
· 2017
[cited by applicant]
JP 6170284B2
· 2017
[cited by applicant]
JP 2017198697A
· 2017
[cited by applicant]
JP 2019537714A
· 2019
[cited by applicant]
SE 524500C2
· 2004
[cited by applicant]
TW 201201847A
· 2012
[cited by applicant]
TW 201825049A
· 2018
[cited by applicant]
TW 201941750A
· 2019
[cited by applicant]
TW 202006742A
· 2020
[cited by applicant]
WO WO9905503A2
· 1999
[cited by applicant]
WO WO2007062135A2
· 2007
[cited by applicant]
WO WO2009084995A1
· 2009
[cited by applicant]
WO WO2010071999A1
· 2010
[cited by applicant]
WO WO2011010231A1
· 2011
[cited by applicant]
WO WO2011077303A1
· 2011
[cited by applicant]
WO WO2011091378A1
· 2011
[cited by applicant]
WO WO2011095580A1
· 2011
[cited by applicant]
WO WO2013059177A1
· 2013
[cited by applicant]
WO WO2013126147A2
· 2013
[cited by applicant]
WO WO2015058151A2
· 2015
[cited by applicant]
WO WO2016087592A1
· 2016
[cited by applicant]
WO WO2018014475A1
· 2018
[cited by applicant]
WO WO2018015953A1
· 2018
[cited by applicant]
WO WO2018081354A1
· 2018
[cited by applicant]
WO WO2019005722A1
· 2019
[cited by applicant]
WO WO2019103912A2
· 2019
[cited by applicant]
WO WO2019136349A2
· 2019
[cited by applicant]
WO WO2020144134A1
· 2020
[cited by applicant]
WO WO2020146032A1
· 2020
[cited by applicant]
WO WO2020190821A1
· 2020
[cited by applicant]
WO WO2020219619A1
· 2020
[cited by applicant]
WO WO2020219620A1
· 2020
[cited by applicant]
WO WO2021061315A1
· 2021
[cited by applicant]
WO WO2022008374A1
· 2022
[cited by applicant]
WO WO2022215530A1
· 2022
[cited by applicant]
WO WO2023057411A9
· 2023
[cited by applicant]
WO WO2023239829A2
· 2023
[cited by applicant]
WO WO2024173297A1
· 2024
[cited by applicant]
WO WO2024211651A1
· 2024
[cited by applicant]
WO WO2025072177A1
· 2025
[cited by applicant]
Ali, A. et al., The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's “M1|RT Comparison”, Europea…
[cited by applicant]
American College of Radiology (ACR) and the Society for Pediatric Radiology (SPR), ACR-SPR Practice Parameter For The Performance Of Skeletal Scintigraphy (Bone Scan), Resolution 28, (2013-Revused2017), available from: …
[cited by applicant]
Anand, A. et al., A Pre-Analytical Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. J Nucl Med. pp. 1865-1871, (20…
[cited by applicant]
Anand, A. et al., Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer, J. Nucl. Med., 57(1):41-45 (2…
[cited by applicant]
Anand, A. et al., Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide, EJNMMI Research, 6:23, 7 pages (2016).
[cited by applicant]
Anand, A. et al., Translating Prostate Cancer Working Group 2 (PCWG2) Progression Criteria into a Quantitative Response Biomarker in Metastatic Castration Resistant Prostate Cancer (mCRPC), ASCO GU Conference, Poster, 1…
[cited by applicant]
Anand, A. et al., Translating Prostate Cancer Working Group 2 (PCWG2) progression criteria into a quantitative response biomarker in metastatic castration-resistant prostate cancer (mCRPC), Journal of Clinical Oncology,…
[cited by applicant]
Armstrong, A. et al., Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC), Urologic Oncology: Seminars and Origin…
[cited by applicant]
Armstrong, A. et al., Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial,…
[cited by applicant]
Armstrong, A. J. et al., Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a R…
[cited by applicant]
Armstrong, A. J. et al., Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC), Meeting Library ASC University, 11 pages (2017).
[cited by applicant]
Bai, P. et. al., Body region localization in whole-body low-dose CT images of PET/CT scans using virtual landmarks, Medical Physics Wiley USA, 46(3): 1286-1299 (2019).
[cited by applicant]
Belal, S. et al., Association of PET Index quantifying skeletal uptake in NaF PET/CT images with overall survival in prostate cancer patients, ASCO GU 2017, Poster 178, 1 page, presented Feb. 16, 2017.
[cited by applicant]
Belal, S. et al., PET Index quantifying skeletal uptake in NaF PET/CT images with overall survival in prostate cancer patients, ASCO GU 2017, Abstract, 1 page, (Feb. 13, 2017).
[cited by applicant]
Belal, S. L. et al, 3D skeletal uptake of 18F sodium fluoride in PET/CT images is associate with overall survival in patients with prostate cancer, EJNMMI Research, 7(15):1-8 (2017).
[cited by applicant]
Belal, S.L. et al., Automated evaluation of normal uptake in different skeletal parts in 18F-sodium fluoride (NaF) PET/CT using a new convolutional neural network method, EJNMMI, EANM '17, 44(Suppl 2):S119-S956, Abstrac…
[cited by applicant]
Blue Earth Diagnostics, Posluma Highlights of Prescribing Information, 12 pages, (2023).
[cited by applicant]
Bombardieri, E. et al., Bone scintigraphy: procedure guidelines for tumour imaging, Eur J. Nucl. Med. Mol. Imaging, 30:BP99-BP106, (2003).
[cited by applicant]
Brynolfsson, J., et. al., Deep Learning based urinary bladder segmentation using 18FDCFPyL (PyL-PSMA) PET/CT images, EPS-145, European Association of Nuclear Medicine, (2020), <http://link.springer.com/article/10.1007/s…
[cited by applicant]
Brynolfsson, J., et. al., Deep Learning-Enabled comprehensive detection and quantification of 18FDCFPyL (PyL-PSMA) PET/CT, OP-548, European Association of Nuclear Medicine, (2020), <http://link.springer.com/article/10.1…
[cited by applicant]
Bushberg, J. T. et al., Essential Physics of Medical Imaging, Essential Physics of Medical Imaging, 19.3: p. 581 (table 15-3), p. 713 paragraph 6, section 19.3 and p. 720, (2011).
[cited by applicant]
Capobianco, N. et. al., Whole-body uptake classification and prostate cancer staging in
[cited by applicant]
Ceci, F. et al., E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET, European Journal of Nuclear Medicine and Molecular Imaging, 48:1626-1638, (2021).
[cited by applicant]
Cha, K. H., et al. Urinary bladder segmentation in CT urography using deep-learning convolutional neural network and level sets, Medical physics, 43(4):1882-1896, (2016).
[cited by applicant]
Chen, X. et al., TensorMask: A Foundation for Dense Object Segmentation, arXiv, 12 pages, (2019).
[cited by applicant]
Chen, X. et al., TensorMask: A Foundation for Dense Object Segmentation, Proceedings of the IEEE/CVF International Conference on Computer Vision (ICCV), 10 pages, (2019).
[cited by applicant]
Christ, P.F. et al., Automatic Liver and Tumor Segmentation of CT and MRI Volumes Using Cascaded Fully Convolutional Neural Networks, Arxiv.org, Cornell University Library, 20 pages, (2017).
[cited by applicant]
Ciernik, I. F., et al. 3D-segmentation of the 18F-choline PET signal for target volume definition in radiation therapy of the prostate, Technology in cancer research & treatment 6(1): 23-30, (2007).
[cited by applicant]
De Brabandere, B. et al., Semantic Instance Segmentation with a Discriminative Loss Function, arXiv preprint, 10 pages, (2017).
[cited by applicant]
Dennis, E. et al., Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer, Journal of Clinical Oncology, 30(5):519-524 (2012).
[cited by applicant]
Dertat, A., Applied Deep Learning—Part 4: Convolutional Neural Networks, Towards Data Science,<http://towardsdatascience.com/applied-deep-learning-part-4-convolutional-neural-networks-584bc134c1e2> 26 pages, (2017).
[cited by applicant]
Eiber, M. et al., Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT, The Journal of Nuclear Medicine, 59(3):469-478, (2018).
[cited by applicant]
Emmett, L. et al., The Primary Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis, J. Nucl. Med., 63(11):1644-1650 (2022).
[cited by applicant]
Fendler, W.P. et. al.,
[cited by applicant]
Gafita, A. et al., Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study, J. Nucl. Med., 63(…
[cited by applicant]
GE Healthcare, SPECT/CT Cameras, 2 pages, retrieved Oct. 25, 2017: <http://www3.gehealthcare.com.sg/en-gb/products/categories/nuclear_medicine/spect-ct_cameras>.
[cited by applicant]
Ghosh, P. and Mitchell, M., Prostate segmentation on pelvic CT images using a genetic algorithm, Proceedings of SPIE, vol. 6914, Medical Imaging 2008: Image Processing, 8 pages, (2008).
[cited by applicant]
Giesel, F. L. et al., F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients, Eur. J. Nucl. Med. Mol. Imaging, 44:678-688 (2017).
[cited by applicant]
Gjertsson, K., et. al., A Novel Automated Deep Learning Algorithm for Segmentation of the Skeleton in Low-Dose CT for [(18)F] DCFPyL PET/CT Hybrid Imaging in Patients with Metastatic Prostate Cancer, Annual Congress of …
[cited by applicant]
Gjertsson, K., Segmentation in Skeletal Scintigraphy Images using Convolutional Neural Networks, Master's Theses in Mathematical Sciences, pp. 39-58, (2017), <https://lup.lub.lu.se/student-papers/search/publication/8916…
[cited by applicant]
Goffin, K. E. et al., Phase 2 study of
[cited by applicant]
Gorthi, S. et al., Segmentation of Head and Neck Lymph Node Regions for Radiotherapy Planning Using Active Contour-Based Atlas Registration, IEEE Journal of Selected Topics in Signal Processing, 3(1):135-147 (2009).
[cited by applicant]
Grahovac, M. et al., Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts, Eur. J. Med. Mol. Imaging, 50(6):1607-1620 (2023).
[cited by applicant]
Guan, H. et al., Automatic Hot Spot Detection and Segmentation in Whole Body FDG-PET Images, IEEE International Conference on Image Processing, 4 pages, (2006).
[cited by applicant]
Guimond, A. et al., Average Brain Models: A Convergence Study, Computer Vision and Image Understanding, 77:192-210 (2000).
[cited by applicant]
Hajnal, J. et al., 4.4 Intensity, Size, and Skew Correction; 7.1 Introduction; 7.2 Methods; 7.3 Image Interpretation—General, In: Medical Image Registration, CRC Press LLC, 80-81:144-148 (2001).
[cited by applicant]
Hatamizadeh, A. et al., UNETR: Transformers for 3D Medical Image Segmentation, Proceedings of the IEEE/CVF Winter Conference on Applications of Computer Vision (WACV), 11 pages, (2022).
[cited by applicant]
He, K. et al., Pelvic Organ Segmentation Using Distinctive Curve Guided Fully Convolutional Networks, IEEE Trans. Med. Imaging, 38(2):585-595 (2019).
[cited by applicant]
Hiller, S. M. et al., 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer, Journal of Nuclear Medicine, 54(8):1369-1376 (2013) retrieved Oct. 25, 2017: …
[cited by applicant]
Horikoshi, H. et al., Computer-aided diagnosis system for bone scintigrams from Japanese patients: importance of training database, Annals of Nuclear Medicine, 26(8):622-626 (2012).
[cited by applicant]
Huang, J.-H. et al., A Set of Image Processing Algorithms for Computer-Aided Diagnosis in Nuclear Medicine Whole Body Bone Scan Images, IEEE Transactions on Nuclear Science, 54(3):514-522 (2007).
[cited by applicant]
Iandola, F.N. et al., SqueezeNet: AlexNet-level accuracy with 50x fewer parameters and <0.5MB model size, arXiv, 13 pages, (2016).
[cited by applicant]
Im, HJ, et. al., et. al., Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?, Nucl. Med. Mol. Imaging, 52(1):5-15, (2018).
[cited by applicant]
Inoue, T., What cancers can be understood and not known by “PET”?—Effects of PET scanning by site, Medical Note Interview, 4 pages, (2015), retrieved from the internet at: https://medicalnote.jp/contents/150715-000003-C…
[cited by applicant]
International Search Report for PCT/US2020/047500, filed Aug. 21, 2020, 3 pages, mailed (Mar. 15, 2021).
[cited by applicant]
Invitation to Pay Additional Fees for PCT/EP2022/077505, filed Oct. 4, 2022, 15 pages, (mailed Feb. 2, 2023).
[cited by applicant]
Johnsson, K. et al., Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting, European Journal of Nuclear Medicin …
[cited by applicant]
Johnsson, K., et. al., miPSMA Index: Comprehensive and Automated Quantification of 18F-DCFPyL (PyL-PSMA) PET/CT for Prostate Cancer Staging, J Nucl Med., 61: (Supplement 1): 1435, 5 pages, (2020).
[cited by applicant]
Kaboteh R. et al., Progression of bone metastases in patients with prostate cancer—automated detection of new lesions and calculation of bone scan index, EJNMMI Research, 3:64, 6 pages, (2013).
[cited by applicant]
Kaboteh, R. et al., Convolutional neural network based quantification of choline uptake in PET/CT studies is associated with overall survival in patents with prostate cancer, EJNMMI, EANM '17, 44(Suppl 2):S119-S956, Abs…
[cited by applicant]
Kawakami, K. et al., Introduction of bone scintigraphy diagnosis support software “Bonenavi” (Topics), Journal of Nuclear Medicine (Japanese), 63:41-51 (2011).
[cited by applicant]
Kawakami, K., Evaluation of bone metastasis by bone scintigraphy diagnostic support software Bonenavi, Communication of the Imaging Group of the JSRT, 36(1):74-77 (2013).
[cited by applicant]
Kertesz, H. et al., Implementation of a Spatially-Variant and Tissue-Dependent Positron Range Correction for PET/CT Imaging, Front. Physiol., 13:818463 (2022).
[cited by applicant]
Kertesz, H. et al., Positron range in combination with point-spread-function correction: an evaluation of different implementations for [124I]-PET imaging, ENJMMI Phys., 9(1):56 (2022).
[cited by applicant]
Khurshid, Z. et al., Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction, Oncotarget., 9(70):33312-33321 (2018).
[cited by applicant]
Kiess, et al., Prostate-specific membrane antigen and a target for cancer imaging and therapy, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 59(3):241-268 (2015).
[cited by applicant]
Kikuchi, A. et al., Automated segmentation of the skeleton in whole-body bone scans: influence of difference in atlas, Nuclear Medicine Communications, 33(9):947-953 (2012).
[cited by applicant]
Kinahan, P.E. et al., PET/CT Standardized Update Values (SUVs) in Clinical Practice and Assessing Response to Therapy, Semin Ultrasound CT MR 31(6):496-505 (2010) retrieved Oct. 25, 2017: <https://www.ncbi.nlm.nih.gov/p…
[cited by applicant]
Knutsson, H., and Andersson, M., Morphons: Segmentation using Elastic Canvas and Paint on Priors, IEEE International Conference on Image Processing (ICIP 2005), Genova, Italy, 4 pages (2005).
[cited by applicant]
Kopka, K. et al., Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers, The Journal of Nuclear Medic…
[cited by applicant]
Krajnc, D. et al., Automated data preparation for in vivo tumor characterization with machine learning, Front. Oncol., 12:1017911 (2022).
[cited by applicant]
Lin, T.Y. et. al., Feature Pyramid Networks for object detection, FAIR, 10 pages, (2016), <https://arxiv.org/abs/1612.03144v1>.
[cited by applicant]
Litjens, G. et al., A survey on deep learning in medical image analysis, Medical Image Analysis, 42:60-88, (2017).
[cited by applicant]
Liu, L. et al., Computer-Aided Detection of Prostate Cancer with MRI: Technology and Applications, Acad Radiol. Author manuscript, 50 pages 2016.
[cited by applicant]
Ma, L. et al., Automatic segmentation of the prostate on CT images using deep learning and multi-atlas fusion, Proc. of SPIE vol. 10133:101332O-1-101332O-9 (2017).
[cited by applicant]
Ma, L. et al., Combining Population and Patient-Specific Characteristics for Prostate Segmentation on 3D CT Images, Proc of SPIE 9784:978427-1-8 (2016).
[cited by applicant]
Ma, L. et al., Random Walk Based Segmentation for the Prostate on 3D Transrectal Ultrasound Images, Proc SPIE Int Soc Opt Eng. Author manuscript, 13 pages (2016).
[cited by applicant]
Matsubara, N. et al., A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases, Clinical Genitourinary Cancer, 000(xxx):1-10, (2021).
[cited by applicant]
Mayo Clinic Staff, Choline C-11 PET scan, Overview, Mayo Clinic, 4 pages (2017), retrieved Oct. 25, 2017: <https://www.mayoclinic.org/tests-procedures/choline-c-11-pet-scan/home/ovc-20156994>.
[cited by applicant]
Meyer, A., et. al., Deep learning algorithm improves identification of men with low-risk prostate cancer using PSMA targeted 99mTc-MIP-1404 SPECT/CT, Journal of Clinical Oncology, 37:(15), (2019).
[cited by applicant]
Milletari, F. et al., V-Net: Fully Convolutional Neural Networks for Volumetric Medical Image Segmentation, 2016 Fourth International Conference on 3D Vision (3DV), 11 pages, (2016).
[cited by applicant]
Nakajima, K. et al., Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project, EJNMMI Research, 3:83, 9 pages, (2013).
[cited by applicant]
National Cancer Institute, NCI Drug Dictionary: gallium Ga 68-labeled PSMA-11, 1 page, retrieved Oct. 25, 2017: <https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=766400>.
[cited by applicant]
National Cancer Institute, NCI Drug Dictionary: technetium Tc 99m methylene diphosphonate, 1 page, retrieved Oct. 25, 2017: <https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=537722>.
[cited by applicant]
Nickols, N. et al., aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in 18F-DCFPyL (PSMA) images of Veterans with Prostate Cancer, Journal of Nuclear Medicine, 26 pages, May 28, 202…
[cited by applicant]
Nickols, N.G., et. al., A deep learning algorithm to predict coexisting metastatic disease using intraprostatic [F18]DCFPYL PSMA image alone in veterans with prostate cancer, Journal of Clinical Oncology 38, (Supplement…
[cited by applicant]
Nogi, S. et al., Metastatic bone tumor quantified by computer-assisted diagnosis system of bone scintigraphy, Nuclear Medicine in Clinic, 45(3):35-37 (2012).
[cited by applicant]
Ohlsson, M., et. al., Automated decision support for bone scintigraphy, Computer-based medical systems, pp. 1-6, (2009).
[cited by applicant]
Papp, L. et al., Glioma Survival Prediction with Combined Analysis of In Vivo 11C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning, J. Nucl. Med., 59(6):892-899 (2018).
[cited by applicant]
Papp, L. et al., Optimized Feature Extraction for Radiomics Analysis of 18F-FDG PET Imaging, J. Nucl. Med., 60(6):864-872 (2019).
[cited by applicant]
Papp, L. et al., Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI, Eur. J. Nucl. Mol. Imaging, 48(6):1795-1805 (2021).
[cited by applicant]
Partin, A.W. et al., Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update, JAMA, 277(18):1445-1451 (1997).
[cited by applicant]
Partin, A.W. et al., The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer, J. Urol., 150(1):110-114 (1993).
[cited by applicant]
Paschalis, A. et al., Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer, European Urology, 76(4):469-478, (2019).
[cited by applicant]
Perera, M. et al., Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis, European U…
[cited by applicant]
Polymeri, E. et al., Analytical validation of an automated method for segmentation of the prostate gland in CT images, EJNMMI, EANM '17, 44(Suppl 2):S119-S956, Abstract EP-0641 (2017).
[cited by applicant]
Polymeri, E., et. al., Deep learning-based quantification of PET/CT prostate gland uptake: association with overall survival, Clinical Physiology Functional Imaging, DOI: 10.1111/cpf.12611, 40(2):106-113, (2019).
[cited by applicant]
Poulakis, V. et al., Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy, Eur. …
[cited by applicant]
Pouliot, F., et. al., Prospective evaluation of a Novel Deep Learning Algorithm (PSMA-AI) in the assessment of 99mTc-MIP-1404 SPECT/CT in patients with low or intermediate risk prostate cancer, Annual Congress of the Eu…
[cited by applicant]
radiologyinfo.org for Patients, Computed Tomography (CT), 2 pages, retrieved Oct. 25, 2017: <https://www.radiologyinfo.org/en/submenu.cfm?pg=ctscan>.
[cited by applicant]
Ren, S., et. al., Faster R-CNN: Towards Real-Time Object Detection with Region Proposal Networks, 14 pages, (2015), <http://image-net.org/challenges/LSVRC/2015/results>.
[cited by applicant]
Ronneberger, O., et. al., U-Net: Convolutional Networks for Biomedical Image Segmentation, Springer International Publishing, pp. 234-241, (2015), <http://lmb.informatik.uni-freiburg.de/>. Published online on Nov. 18, 2…
[cited by applicant]
Rowe, S. P. et al., PET Imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges, Prostate Cancer and Prostatic Diseases, pp. 1-8 (2016).
[cited by applicant]
Rowe, S. P. et al., PSMA-Based [
[cited by applicant]
Sabbatini, P. et al., Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer, Journal of Clinical Oncology, 17(3):948-957 (1999).
[cited by applicant]
Sadik, M. et al., 3D prostate gland uptake of 18F-choline—association with overall survival in patients with hormone-naïve prostate cancer, The Journal of Nuclear Medicine, 58(Suppl. 1):Abstract 544, 2 pages, (2017).
[cited by applicant]
Sadik, M. et al., A new computer-based decision-support system for the interpretation of bone scans, Nuclear Medicine Communications, 27(5):417-423 (2006).
[cited by applicant]
Sadik, M. et al., Automated 3D segmentation of the prostate gland in CT images—a first step towards objective measurements of prostate uptake in PET and SPECT images, Journal of Nuclear Medicine, 58(1):1074, (2017).
[cited by applicant]
Sadik, M. et al., Automated quantification of reference levels in liver and mediastinum (blood pool) for the Deauville therapy response classification using FDG-PET/CT in lymphoma patients, EJNMMI, EANM '17, 44(Suppl 2)…
[cited by applicant]
Sadik, M. et al., Computer-assisted interpretation of planar whole-body bone scans, Journal Nuclear Medicine, 49(12):1958-65, 2008.
[cited by applicant]
Sadik, M. et al., Convolutional neural networks for segmentation of 49 selected bones in CT images show high reproducibility, EJNMMI, EANM '17, 44(Suppl 2):S119-S956, Abstract OP-657 (2017).
[cited by applicant]
Sadik, M. et al., Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study, Journal of Nuclear Medicine, 50(3): 368-75, 200…
[cited by applicant]
Sadik, M. et al., Variability in reference levels for Deauville classifications applied to lymphoma patients examined with 18F-FDG-PET/CT, EJNMMI, EANM '17, 44(Suppl 2):S119-S956, Abstract EP-0771 (2017).
[cited by applicant]
Sajn, L. et al., Computerized segmentation of whole-body bone scintigrams and its use in automated diagnostics, Computer Methods and Programs in Biomedicine, 80:47-55 (2005).
[cited by applicant]
Salerno, J. et al., Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: A Cancer Care Ontario clinical practice guideline, Canadian Urological Association Journal, 10(9-10):332…
[cited by applicant]
Santos-Cuevas, C. et al. 99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients, Nuclear Medicine and Biology 52:1-6, (2017).
[cited by applicant]
Seifert, R. et al., Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2), Eur. Urol., 83(5):405-412 (2023).
[cited by applicant]
Shi, F. et al., Deep learning empowered volume delineation of whole-body organs-at-risk for accelerated radiotherapy, Nat. Commun., 13(1):6566 (2022).
[cited by applicant]
Sjöstrand K. et al., Statistical regularization of deformation fields for atlas-based segmentation of bone scintigraphy images, MICCAI 5761:664-671 (2009).
[cited by applicant]
Sjöstrand, K., et. al., Automated detection and quantification of Prostatic PSMA uptake in SPECT/CT using a Deep Learning Algorithm for Segmentation of Pelvic Anatomy, The Journal of Nuclear Medicine, 59(1):p. 30, (2018…
[cited by applicant]
Sjostrand, K., et al., Automated Assessment of Prostatic PSMA Expression in SPECT/CT using Deep Convolutional Neural Networks—A Prospectively Planned Retrospective Analysis of Phase 3 Study MIP-1404-3301, The Journal of…
[cited by applicant]
Sluimer, I. et al., Toward Automated Segmentation of the Pathological Lung in CT, IEEE Transactions on Medical Imaging, 24(8):1025-1038 (2005).
[cited by applicant]
Teng, C. et al., Head and neck lymph node region delineation using a hybrid image registration method, 3rd IEEE International Symposium on Biomedical Imaging: Nano to Macro, 4 pages, (2006).
[cited by applicant]
Tian, Z. et al., A fully automatic multi-atlas based segmentation method for prostate MR images, Proc SPIE Int Soc Opt Eng. Author manuscript, 12 pages (2015).
[cited by applicant]
Tian, Z. et al., A supervoxel-based segmentation method for prostate MR images, Med. Phys., 44(2):558-569 (2017).
[cited by applicant]
Tian, Z. et al., Deep convolutional neural network for prostate MR segmentation, Proc. of SPIE 10135:101351L-1-101351L-6 12 pages, (2017).
[cited by applicant]
Tian, Z., et al., Superpixel-based Segmentation for 3D Prostate MR Images, IEEE Trans Med Imaging, Author manuscript, pp. 558-569, (2016).
[cited by applicant]
Trägärdh, E., et. al., RECOMIA—a cloud-based platform for artificial intelligence research in nuclear medicine and radiology, EJNMMI Physics, <https://doi.org/10.1186/s40658-020-00316-9>, 7:51, 12 pages, (2020).
[cited by applicant]
Ulmert, D. et al., A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index, European Urology, 62(1):78-84 (2012).
[cited by applicant]
US Food and Drug Administration, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, 21 pages, (2018).
[cited by applicant]
Valladares, A. et al., A multi-modality physical phantom for mimicking tumor heterogeneity patterns in PET/CT and PET/MRI, Med. Phys., 49(9):5819-5829 (2022).
[cited by applicant]
Wallis, J.W. et. al., Three-dimensional display in nuclear medicine, IEEE Trans Med Imaging, 8(4):297-303, (1989).
[cited by applicant]
Washino, H., Injectable for bone scintigraphy: Technetium hydroxymethylenediphosphonate (99mTc) injection solution (Revised Edition), 9 pages, (2007), retrieved from the internet at:https://rada.or.jp/database/home4/nor…
[cited by applicant]
Wrangsjo, A. et al., Non-rigid Registration Using Morphons, Proceedings of the 14th Scandinavian Conference on Image Analysis (SCIA '05), pp. 501-510 (2005).
[cited by applicant]
Written Opinion for PCT/US2020/047500, filed Aug. 21, 2020, 6 pages, mailed (Mar. 15, 2021).
[cited by applicant]
Yin, T.-K., and Chiu, N.T., A Computer-Aided Diagnosis for Locating Abnormalities in Bone Scintigraphy by a Fuzzy System With a Three-Step Minimization Approach, IEEE Transactions on Medical Imaging, 23(5):639-654 (2004…
[cited by applicant]
Benitez, C.M. et al., Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tra…
[cited by applicant]
Pizzuto, D.A. et al., The central zone has increased 68Ga-PSMA-11 uptake: “Mickey Mouse ears” can be hot on 68Ga-PSMA-11 PET, Eur. J. Nucl. Med. Mol. Imaging, 45(8):1335-1343 (2018).
[cited by applicant]
Wan, H., Automated Contouring Using Neural Networks, Contour Protege AI White Paper, 3 pages, (2020), <https://go.mimsoftware.com/contour-protegeai-plus/white-paper>.
[cited by applicant]
Afshar-Oromieh, A. et al., Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing, Eur. J. Nucl. Med. Mol. Imaging, 43(9):1611-1620 (2016).
[cited by applicant]
Gandaglia, G. et al., Distribution of metastatic sites in patients with prostate cancer: A population-based analysis, Prostate, 74(2):210-216 (2014).
[cited by applicant]
Giesel, F.L. et al., (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617, Eur. J. Nucl. Med. Mol. Imaging, 43(10):1929-1930 (2016).
[cited by applicant]
Greenspan, H. et al., Deep Learning in Medical Imaging: Overview and Future Promise of an Exciting New Technique, IEEE Transactions on Medical Imaging, 35(5):1153-1159 (2016).
[cited by applicant]
Guntur, A.R. and Rosen, C.J., Bone as an endocrine organ, Endocr. Pract., 18(5):758-762 (2012).
[cited by applicant]
Kaur, D. and Kaur, Y., Various Image Segmentation Techniques: A Review, International Journal of Computer Science and Mobile Computing, 3(5):809-814 (2014).
[cited by applicant]
Nitta, S. et al., Assisted Diagnosis System by Automatic Extraction of Tumor Candidate Areas from PET/CT Images, Medical Imaging Technology, 24(3):181-190 (2006). English translation included.
[cited by applicant]
Seifert, S. et al., Hierarchical parsing and semantic navigation of full body CT data, Medical Imaging 2009: Image Processing, Proceedings of SPIE vol. 7259, 8 pages, (2009).
[cited by applicant]
Sharma, N. and Aggarwal, L.M., Automated medical image segmentation techniques, J. Med. Phys., 35(1):3-14 (2010).
[cited by applicant]
Shen, D. et al., Deep Learning in Medical Image Analysis, Annu. Rev. Biomed. Eng., 19:221-248 (2017).
[cited by applicant]
Weineisen, M. et al., 68Ga- and 177Lu-Labeled Psma I&T: Optimization of a PSMA—Targeted Theranostic Concept and First Proof-of-Concept Human Studies, J. Nucl. Med., 56(8):1169-1176 (2015).
[cited by applicant]
Cited By (4)